The estimated Net Worth of Michael H Tardugno is at least $1.73 Millón dollars as of 12 April 2022. Mr. Tardugno owns over 4,000 units of Imunon Inc stock worth over $32,365 and over the last 17 years he sold CLSN stock worth over $0. In addition, he makes $1,694,790 as Executive Chairman of the Board, President y Chief Executive Officer at Imunon Inc.
Sign up
Mr. Tardugno CLSN stock SEC Form 4 insiders trading
Michael has made over 33 trades of the Imunon Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of CLSN stock worth $14,120 on 12 April 2022.
The largest trade he's ever made was exercising 33,333 units of Imunon Inc stock on 19 January 2008 worth over $65,333. On average, Michael trades about 4,061 units every 88 days since 2008. As of 12 April 2022 he still owns at least 16,513 units of Imunon Inc stock.
You can see the complete history of Mr. Tardugno stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Tardugno biography
Michael H. Tardugno is Executive Chairman of the Board, President, Chief Executive Officer of Celsion Corporation., effective October 7, 2014. Mr. Tardugno was appointed by the Board of Directors as the Chairman as successor to Max E. Link, Ph.D., who passed away in October 2014. Prior to joining the Company and for the period from February 2005 to December 2006, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies, Inc., a subsidiary of Mylan Inc. From 1998 to 2005, Mr. Tardugno was Executive Vice President of Songbird Hearing, Inc., a medical device company spun out of Sarnoff Corporation. From 1996 to 1998, he was Senior Vice President of Technical Operations worldwide for a division of Bristol-Myers Squibb, and from 1977 to 1995, he held increasingly senior executive positions including Senior Vice-President of World-wide Technology Development with Bausch & Lomb and Abbott Laboratories. Mr. Tardugno holds a B.S. degree from St. Bonaventure University and completed the Harvard Business School Program for Management Development.
What is the salary of Michael Tardugno?
As the Executive Chairman of the Board, President y Chief Executive Officer of Imunon Inc, the total compensation of Michael Tardugno at Imunon Inc is $1,694,790. There are no executives at Imunon Inc getting paid more.
How old is Michael Tardugno?
Michael Tardugno is 64, he's been the Executive Chairman of the Board, President y Chief Executive Officer of Imunon Inc since 2014. There are 3 older and 8 younger executives at Imunon Inc. The oldest executive at Imunon Inc is Michael H. Tardugno, 70, who is the Exec. Chairman, Pres & CEO.
What's Michael Tardugno's mailing address?
Michael's mailing address filed with the SEC is C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ, 08648.
Insiders trading at Imunon Inc
Over the last 17 years, insiders at Imunon Inc have traded over $895,739 worth of Imunon Inc stock and bought 973,579 units worth $2,229,348 . The most active insiders traders include Gary W Pace, Max Link y Sean F. Moran. On average, Imunon Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,407. The most recent stock trade was executed by Michael H Tardugno on 12 April 2022, trading 4,000 units of CLSN stock currently worth $14,120.
What does Imunon Inc do?
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
What does Imunon Inc's logo look like?
Complete history of Mr. Tardugno stock trades at Imunon Inc
Imunon Inc executives and stock owners
Imunon Inc executives and other stock owners filed with the SEC include:
-
Michael Tardugno,
Executive Chairman of the Board, President, Chief Executive Officer -
Michael H. Tardugno,
Exec. Chairman, Pres & CEO -
Nicholas Borys,
Senior Vice President and Chief Medical Officer -
Jeffrey Church,
Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer -
Dr. Nicholas Borys,
Exec. VP & Chief Medical Officer -
Jeffrey W. Church CPA, CPA,
CFO, Exec. VP & Corp. Sec. -
Dr. Khursheed Anwer M.B.A., Ph.D.,
Exec. VP & Chief Scientific Officer -
Khursheed Anwer,
Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy -
Dr. Khursheed Anwer,
Exec. VP & Chief Scientific Officer -
Andreas Voss,
Independent Director -
Alberto Martinez,
Independent Director -
Robert Hooper,
Independent Director -
Frederick Fritz,
Independent Director -
Pok Yu Chow,
Independent Director -
Donald Braun,
Independent Director -
Marianne M. Lambertson,
VP of Communications & Investor Relations -
Timothy J. Tumminello,
Chief Accounting Officer & Controller -
Sean F. Moran,
Chief Financial Officer -
Gary W Pace,
Director -
Stacy Lindborg,
Director -
Christine A Pellizzari,
Director -
Timothy J Tumminello,
Controller -
Inc. Fka Egen, Inc. Egwu,,
10% owner -
Max Link,
Director -
Gregory L Weaver,
Director -
Goff Corinne Le,
President and CEO -
Constantine John Kardaras,
Chief Accounting Officer